Biotech News

Rallybio Reports Third Quarter 2025 Financial Results and Provides Business Updates

Rallybio (RLYB)Rallybio2025-11-06 13:00 ESTEarnings

– RLYB116 Confirmatory PK/PD Study Data Expected in 4Q 2025 – – Generated $20 Million from Sale of Interest in REV102 – – Cash Runway Extended through 2027 – NEW HAVEN, Conn. --(BUSINESS WIRE)--Nov. 6, 2025-- Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating

Related news

MNPRMonopar2026-05-14 18:00 EST

Monopar Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates

EDITEditas Medicine2026-08-05 20:01 EST

Editas Medicine Announces Second Quarter 2026 Results and Business Updates

RAREUltragenyx Pharmaceutical2026-08-04 20:05 EST

Ultragenyx Reports Second Quarter 2026 Financial Results and Corporate Update

KRYSKrystal Biotech2026-08-03 11:00 EST

Krystal Biotech Announces Second Quarter 2026 Financial and Operating Results

PTCTPTC Therapeutics, Inc.2026-07-30 20:01 EST

PTC Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results

PHVSPharvaris2026-05-12 20:05 EST

Pharvaris Reports First Quarter 2026 Financial Results and Provides Business Update

CRNXCrinetics Pharmaceuticals2026-05-07 20:05 EST

Crinetics Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update

PTCTPTC Therapeutics, Inc.2026-05-07 20:01 EST

PTC Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results

BCRXBioCryst Pharmaceuticals2026-05-06 11:00 EST

BioCryst Reports First Quarter 2026 Financial Results and Provides Business Update

RAREUltragenyx Pharmaceutical2026-05-05 20:01 EST

Ultragenyx Reports First Quarter 2026 Financial Results and Corporate Update

View all latest news

Rallybio

Rallybio is a rare-disease biotechnology company focused on complement and immune-mediated disorders. Its pipeline aims at high-unmet-need conditions where targeted biology matters.

Recent company news

RLYBRallybio2026-06-01 12:00 EST

Rallybio Corporation and Avenzo Therapeutics Announce Merger Agreement to Advance Next-Generation Oncology Therapies and $215 Million Concurrent Private Placement

RLYBRallybio2026-03-02 13:00 EST

Rallybio Corporation and Candid Therapeutics Announce Merger Agreement

RLYBRallybio2026-02-17 13:00 EST

Rallybio Announces Positive Data for RLYB116 Phase 1 Study Demonstrating Complete and Sustained Inhibition of Terminal Complement

RLYBRallybio2026-02-03 21:05 EST

Rallybio Announces Reverse Stock Split of Common Stock

RLYBRallybio2025-11-06 13:00 EST

Rallybio Reports Third Quarter 2025 Financial Results and Provides Business Updates

Stock data

Close: 16.19 USD
Market cap: 94.13M USD
Exchange: NASDAQ
Sector: Biopharma
Location: United States